Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 108,008 shares of the medical equipment provider’s stock after selling 7,903 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.05% of Zimmer Biomet worth $9,712,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ZBH. Brighton Jones LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $204,000. Sivia Capital Partners LLC acquired a new stake in shares of Zimmer Biomet in the second quarter valued at about $232,000. United Bank grew its position in shares of Zimmer Biomet by 10.7% in the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after purchasing an additional 1,153 shares during the period. Federated Hermes Inc. grew its position in shares of Zimmer Biomet by 129.2% in the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 1,202 shares during the period. Finally, Cerity Partners LLC grew its position in shares of Zimmer Biomet by 93.6% in the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after purchasing an additional 37,116 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.8%

ZBH opened at $83.07 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 1.10. The company’s 50 day simple moving average is $92.53 and its two-hundred day simple moving average is $92.72. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.83 and a 1-year high of $108.29. The firm has a market capitalization of $16.08 billion, a price-to-earnings ratio of 21.58, a price-to-earnings-growth ratio of 1.91 and a beta of 0.48.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same period last year, the company posted $1.81 EPS. The business’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. Zimmer Biomet’s payout ratio is 24.94%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.28% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Sanford C. Bernstein lifted their target price on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research report on Friday, January 9th. JPMorgan Chase & Co. dropped their target price on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research report on Wednesday. Wells Fargo & Company decreased their price target on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Stifel Nicolaus dropped their price objective on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $94.00 to $120.00 in a report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $102.43.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.